In last trading session, Pulmonx Corp (NASDAQ:LUNG) saw 0.46 million shares changing hands with its beta currently measuring 0.59. Company’s recent per share price level of $6.76 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $269.02M. That closing price of LUNG’s stock is at a discount of -48.08% from its 52-week high price of $10.01 and is indicating a premium of 19.23% from its 52-week low price of $5.46. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.32 million shares which gives us an average trading volume of 325.87K if we extend that period to 3-months.
For Pulmonx Corp (LUNG), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.57. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.4 in the current quarter.
Pulmonx Corp (NASDAQ:LUNG) trade information
Pulmonx Corp’s shares saw a change of -0.44% in year-to-date performance and have moved -0.88% in past 5-day. Pulmonx Corp (NASDAQ:LUNG) showed a performance of -9.14% in past 30-days. Number of shares sold short was 1.17 million shares which calculate 2.36 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 10 to the stock, which implies a rise of 32.4% to its current value. Analysts have been projecting 10 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -47.93% in reaching the projected high whereas dropping to the targeted low would mean a loss of -47.93% for stock’s current value.
Pulmonx Corp (LUNG) estimates and forecasts
This year revenue growth is estimated to rise 15.74% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 22.03M for the same. And 7 analysts are in estimates of company making revenue of 23.73M in the next quarter. Company posted 18.85M and 20.78M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -19.80% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -7.39% while estimates for its earnings growth in next 5 years are of 10.09%.
Pulmonx Corp (NASDAQ:LUNG)’s Major holders
Insiders are in possession of 5.84% of company’s total shares while institution are holding 93.35 percent of that, with stock having share float percentage of 99.14%. Investors also watch the number of corporate investors in a company very closely, which is 93.35% institutions for Pulmonx Corp that are currently holding shares of the company. PRIMECAP MANAGEMENT CO/CA/ is the top institutional holder at LUNG for having 5.71 million shares of worth $36.2 million. And as of 2024-06-30, it was holding 14.6622 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 5.28 million shares on 2024-06-30. The number of shares represents firm’s hold over 13.5609 of outstanding shares, having a total worth of $33.48 million.
On the other hand, PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund and Fidelity Securities Fund-Fidelity Small Cap Growth Fund are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025 , the former fund manager was holding 3.81 shares of worth $25.75 million or 9.57% of the total outstanding shares. The later fund manager was in possession of 1.49 shares on Jan 31, 2025 , making its stake of worth around $10.1 million in the company or a holder of 3.75% of company’s stock.
